Steven Y. Yap
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Steven Y. Yap has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Graeme. J. Stasiuk
Department of Imaging Chemistry and Biology, School of Biomedical Engineering and Imaging Sciences, King’s College London, London SE1 7EH, UK
3 shared publications Huguette Savoie
Department of Chemistry and Biochemistry, Faculty of Science and Engineering, University of Hull, UK
3 shared publications- James Richard Baker
Department of Chemistry, University College London, 20 Gordon Street, London, WC1H 0AJ, UK
2 shared publications - Richard J. Spears
Department of Chemistry, University College London, 20 Gordon Street, London WC1H 0AJ, UK
2 shared publications - Ross William Boyle
Department of Chemistry and Biochemistry University of Hull Cottingham Road Hull E. Yorkshire HU6 7RX UK
2 shared publications - Vijay Chudasama
University College London
2 shared publications
Latest Publications
- Open Access
- 2 May 2024
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 15 (22) , 8557-8568
Chemo- and regio-selective differential modification of native cysteines on an antibody via the use of dehydroalanine forming reagents
Use of dehydroalanine-forming reagents to enable the first example of differentially modifying the native solvent accessible cysteines on an antibody.
- 2 May 2024
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 15 (22) , 8557-8568
Open AccessChemo- and regio-selective differential modification of native cysteines on an antibody via the use of dehydroalanine forming reagents
Use of dehydroalanine-forming reagents to enable the first example of differentially modifying the native solvent accessible cysteines on an antibody.
- Open Access
- 2 April 2022
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 58 (35) , 5359-5362
Unearthing the unique stability of thiophosphonium-C-terminal cysteine adducts on peptides and proteins
Herein we report the remarkable stability of C-terminal thiophosphonium species on small molecules, peptides and proteins.
- 2 April 2022
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 58 (35) , 5359-5362
Open AccessUnearthing the unique stability of thiophosphonium-C-terminal cysteine adducts on peptides and proteins
Herein we report the remarkable stability of C-terminal thiophosphonium species on small molecules, peptides and proteins.
- Open Access
- 20 March 2021
- Published by Oxford University Press (OUP) in Brain
- Vol. 144 (8) , 2284-2290
Discriminatory ability of next-generation tau PET tracers for Alzheimer’s disease
A next generation of tau PET tracers for the imaging of Alzheimer’s disease and other dementias has recently been developed. Whilst the new compounds have now entered clinical studies, there is limited information available to assess their suitability for clinical applications. Head-to-head comparisons are urgently needed to understand differences in the radiotracer binding profiles. We characterized the binding of the tau tracers PI2620, RO948, MK6240 and JNJ067 in human post-mortem brain tissue from a cohort of 25 dementia cases and age-matched controls using quantitative phosphorimaging with tritium-labelled radiotracers in conjunction with phospho-tau specific immunohistochemistry. The four radiotracers depicted tau inclusions composed of paired helical filaments with high specificity, both in cases with Alzheimer’s disease and in primary tauopathy cases with concomitant Alzheimer’s disease pathology. In contrast, cortical binding to primary tauopathy in cases without paired helical filament tau was found to be within the range of age-matched controls. Off-target binding to monoamine oxidase B has been overcome, as demonstrated by heterologous blocking studies in basal ganglia tissue. The high variability of cortical tracer binding within the Alzheimer’s disease group followed the same pattern with each tracer, suggesting that all compounds are suited to differentiate Alzheimer’s disease from other dementias.
- 20 March 2021
- Published by Oxford University Press (OUP) in Brain
- Vol. 144 (8) , 2284-2290
Open AccessDiscriminatory ability of next-generation tau PET tracers for Alzheimer’s disease
A next generation of tau PET tracers for the imaging of Alzheimer’s disease and other dementias has recently been developed. Whilst the new compounds have now entered clinical studies, there is limited information available to assess their suitability for clinical applications. Head-to-head comparisons are urgently needed to understand differences in the radiotracer binding profiles. We characterized the binding of the tau tracers PI2620, RO948, MK6240 and JNJ067 in human post-mortem brain tissue from a cohort of 25 dementia cases and age-matched controls using quantitative phosphorimaging with tritium-labelled radiotracers in conjunction with phospho-tau specific immunohistochemistry. The four radiotracers depicted tau inclusions composed of paired helical filaments with high specificity, both in cases with Alzheimer’s disease and in primary tauopathy cases with concomitant Alzheimer’s disease pathology. In contrast, cortical binding to primary tauopathy in cases without paired helical filament tau was found to be within the range of age-matched controls. Off-target binding to monoamine oxidase B has been overcome, as demonstrated by heterologous blocking studies in basal ganglia tissue. The high variability of cortical tracer binding within the Alzheimer’s disease group followed the same pattern with each tracer, suggesting that all compounds are suited to differentiate Alzheimer’s disease from other dementias.
- Open Access
- 12 August 2020
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 56 (75) , 11090-11093
Synthesis of a porphyrin with histidine-like chelate: an efficient path towards molecular PDT/SPECT theranostics
“Click” chemistry was utilised to synthesis multifunctional theranostic drugs with therapeutic, diagnostic, and prostate-cancer targeting capabilities, paving a path towards “personalised” medicine ultimately improving patients' quality of life.
- 12 August 2020
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 56 (75) , 11090-11093
Open AccessSynthesis of a porphyrin with histidine-like chelate: an efficient path towards molecular PDT/SPECT theranostics
“Click” chemistry was utilised to synthesis multifunctional theranostic drugs with therapeutic, diagnostic, and prostate-cancer targeting capabilities, paving a path towards “personalised” medicine ultimately improving patients' quality of life.
- 18 February 2020
- Published by Wiley in Chemistry – A European Journal
- Vol. 26 (34) , 7602-7608
Evaluation of a Bispidine‐Based Chelator for Gallium‐68 and of the Porphyrin Conjugate as PET/PDT Theranostic Agent
In this study a bispidine ligand has been applied to the complexation of gallium(III) and radiolabelled with gallium‐68 for the first time. Despite its 5‐coordinate nature, the resulting complex is stable in serum for over two hours, demonstrating a ligand system well matched to the imaging window of gallium‐68 positron emission tomography (PET). To show the versatility of the bispidine ligand and its potential use in PET, the bifunctional chelator was conjugated to a porphyrin, producing a PET/PDT‐theranostic, which showed the same level of stability to serum as the non‐conjugated gallium‐68 complex. The PET/PDT complex killed >90 % of HT‐29 cells upon light irradiation at 50 μm. This study shows bispidines have the versatility to be used as a ligand system for gallium‐68 in PET.
- 18 February 2020
- Published by Wiley in Chemistry – A European Journal
- Vol. 26 (34) , 7602-7608
Evaluation of a Bispidine‐Based Chelator for Gallium‐68 and of the Porphyrin Conjugate as PET/PDT Theranostic Agent
In this study a bispidine ligand has been applied to the complexation of gallium(III) and radiolabelled with gallium‐68 for the first time. Despite its 5‐coordinate nature, the resulting complex is stable in serum for over two hours, demonstrating a ligand system well matched to the imaging window of gallium‐68 positron emission tomography (PET). To show the versatility of the bispidine ligand and its potential use in PET, the bifunctional chelator was conjugated to a porphyrin, producing a PET/PDT‐theranostic, which showed the same level of stability to serum as the non‐conjugated gallium‐68 complex. The PET/PDT complex killed >90 % of HT‐29 cells upon light irradiation at 50 μm. This study shows bispidines have the versatility to be used as a ligand system for gallium‐68 in PET.
- 25 June 2018
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 54 (57) , 7952-7954
Selective radiolabelling with 68 Ga under mild conditions: a route towards a porphyrin PET/PDT theranostic agent
A theranostic conjugate for use as a positron emission tomography (PET) radiotracer and as a photosensitiser for photodynamic therapy (PDT) has been synthesised. A water-soluble porphyrin was coupled with the bifunctional chelate, H4Dpaa.ga. This conjugate is capable of rapid 68Ga complexation under physiological conditions; with 93% and 80% radiochemical yields achieved, at pH 4.5 and pH 7.4 respectively, in 15 min at 25 °C. Photocytotoxicity was evaluated on HT-29 cells and showed the conjugate was capable of >50% cell death at 50 μM upon irradiation with light, while causing minimal toxicity in the absence of light (>95% cell survival).
- 25 June 2018
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 54 (57) , 7952-7954
Selective radiolabelling with 68 Ga under mild conditions: a route towards a porphyrin PET/PDT theranostic agent
A theranostic conjugate for use as a positron emission tomography (PET) radiotracer and as a photosensitiser for photodynamic therapy (PDT) has been synthesised. A water-soluble porphyrin was coupled with the bifunctional chelate, H4Dpaa.ga. This conjugate is capable of rapid 68Ga complexation under physiological conditions; with 93% and 80% radiochemical yields achieved, at pH 4.5 and pH 7.4 respectively, in 15 min at 25 °C. Photocytotoxicity was evaluated on HT-29 cells and showed the conjugate was capable of >50% cell death at 50 μM upon irradiation with light, while causing minimal toxicity in the absence of light (>95% cell survival).